nurofen 200 mg ārstnieciskais plāksteris
reckitt benckiser (poland) s.a., poland - ibuprofēns - Ārstnieciskais plāksteris - 200 mg
ibugard 60 mg supozitoriji
pharmaceutical works polpharma sa, poland - ibuprofēns - supozitorijs - 60 mg
ibugard 125 mg supozitoriji
pharmaceutical works polpharma sa, poland - ibuprofēns - supozitorijs - 125 mg
ibutop 50 mg/g gels
hwi pharma services gmbh, germany - ibuprofēns - gels - 50 mg/g
cathejell with lidocaine 20 mg/0,5 mg/g gels
pharmazeutische fabrik montavit gmbh, austria - chlorhexidini dihydrochloridum, lidocaini hydrochloridum - gels - 20 mg/0,5 mg/g
truvivity by nutrilite™ truwithin™ supplement (2019.) tablete
access business group, llc - tablete
truvivity by nutrilite™ truwithin™ drink (2019.) pulveris
access business group, llc - pulveris
nutrilite™ balance within™ (2021.) pulveris, -
pulveris, -
aclasta
sandoz pharmaceuticals d.d. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - zāles kaulu slimību ārstēšanai - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. attieksmi pret osteoporozi, kas saistītas ar ilgtermiņa sistēmisko glikokortikoīdu terapija sievietēm pēc menopauzes un vīriešiem paaugstināts risks lūzums. Ārstēšana paget ir slimības ar kaulu.
mekinist
novartis europharm limited - trametinib - melanoma - antineoplastiski līdzekļi - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 un 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. nav maza šūnu plaušu vēzis (nsclc)trametinib kopā ar dabrafenib ir norādīts ārstēšanai pieaugušiem pacientiem ar progresējošu ne-maza šūnu plaušu vēzis ar braf v600 mutācijas.